Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06526039Phase 3Not Yet Recruiting

A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB

Role: collaborator

NCT04433195Not ApplicableUnknown

Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis

Role: collaborator

NCT02329873Not ApplicableCompleted

Respiratory Rehabilitation Exercises in Older Adults With Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Role: lead

All 3 trials loaded